Results 1 to 10 of about 820 (178)

Toward a Topology-Based Therapeutic Design of Membrane Proteins: Validation of NaPi2b Topology in Live Ovarian Cancer Cells [PDF]

Frontiers in Molecular Biosciences, 2022
NaPi2b is a sodium-dependent phosphate transporter that belongs to the SLC34 family of transporters which is mainly responsible for phosphate homeostasis in humans.
Leisan Bulatova, Daria Savenkova, Alsina Nurgalieva, Daria Reshetnikova, Arina Timonina, Vera Skripova, Mikhail Bogdanov, Mikhail Bogdanov, Ramziya Kiyamova   +8 more
doaj   +8 more sources

T330M Substitution in the Sodium-Dependent Phosphate Transporter NaPi2b Abolishes the Efficacy of Monoclonal Antibodies Against MX35 Epitope [PDF]

Antibodies
Background: Monoclonal antibodies against the sodium-dependent phosphate transporter NaPi2b (SLC34A2) represent a promising approach in the treatment of ovarian and lung cancer.
Leisan F. Bulatova, Vera S. Skripova, Aisylu R. Sagdeeva, Ramilia A. Vlasenkova, Tatiana A. Bugaenko, Rezeda R. Galimova, Alfiya I. Nesterova, Yuliya V. Filina, Ramziya G. Kiyamova   +8 more
doaj   +6 more sources

Recognition of the sodium-dependent phosphate transporter NaPi2b by monoclonal antibodies N-NaPi2b in ovarian cancer cells [PDF]

Учёные записки Казанского университета: Серия Естественные науки, 2020
The sodium-dependent phosphate cotransporter NaPi2b encoded by the SLC34A2 gene is a transmembrane protein that belongs to the family of phosphate transporters SLC34 and is involved in maintaining phosphate homeostasis in the human body.
L.F. Minigulova, V.S. Skripova, A.K. Nurgalieva, D.V. Savenkova, A.S. Kozlova, N.I. Akberova, D.D. Reshetnikova, L.A. Savinska, O.M. Garifulin, M.V. Bogdanov, R.G. Kiyamova   +10 more
doaj   +3 more sources

Targeting NaPi2b in ovarian cancer [PDF]

Cancer Treatment Reviews, 2023
Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy. Despite the success of PARP inhibitors, treatment options are limited, particularly in the platinum-resistant setting.
Banerjee, S, Drapkin, R, Richardson, DL, Birrer, M   +3 more
core   +8 more sources

Identification of phosphate transporter NaPi2b as MX35 cancer antigen by modified SEREX approach [PDF]

Biopolymers and Cell, 2008
© R. G. KIYAMOVA, V. S. GRYSHKOVA, V. S. USENKO, Y. S. KHOZAENKO, V. A. GURTOVYY, B. YIN, G. RITTER, L. OLD, I. T. GOUT, V. V. FILONENKO, 2008.In this study we describe the identification of sodium-dependent phosphate transporter NaPi2b as MX35 cancer-associated antigen.
Kiyamova, R.G., Gryshkova, V.S., Usenko, V.S., Khozaenko, Y.S., Gurtovyy, V.A., Yin, B., Ritter, G., Old, L., Gout, I.T., Filonenko, V.V.   +9 more
core   +5 more sources

Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer [PDF]

Biochemistry and Biophysics Reports, 2021
The high mortality rate from ovarian cancer is due to the asymptomatic nature of the course of the disease, which leads to the diagnosis of ovarian cancer in later stages.
A.K. Nurgalieva, V.E. Popov, V.S. Skripova, L.F. Bulatova, D.V. Savenkova, R.A. Vlasenkova, S.Z. Safina, E. Zh Shakirova, V.V. Filonenko, M.V. Bogdanov, R.G. Kiyamova   +10 more
doaj   +4 more sources

Isolation and functional properties of highly-purified N-terminal domain of human NaPi2b by scalable "resin overload" technique. [PDF]

Anal Biochem
Despite the enthusiasm and advances in the purification of native and engineered full-length membrane proteins, little attention has been paid to their fragments which could serve as attractive inspiration for function, regulation, or targeting of full-length membrane protein with therapeutic antibodies (Abs).
Savenkova D, Makarenko I, Nedorezova D, Kiyamova R, Bogdanov M.   +4 more
europepmc   +5 more sources

Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b. [PDF]

Journal of Clinical Oncology, 2019
3010 Background: XMT-1536 is a Dolaflexin ADC targeting the sodium-phosphate cotransporter NaPi2b, expressed in ovarian, non-squamous lung, papillary thyroid, endometrial, papillary renal and salivary duct cancers. Methods: In this ongoing Phase 1 study, pts with solid tumors likely to express NaPi2b, who progressed on standard therapy, are treated ...
Anthony W. Tolcher, Susanna Varkey Ulahannan, Kyriakos P. Papadopoulos, William Jeffery Edenfield, Ursula A. Matulonis, Timothy F. Burns, Rebecca Mosher, Barbara Fielman, Eric Hailman, Howard A. Burris, Kathleen N. Moore, Erika Paige Hamilton   +11 more
  +9 more sources

Design, synthesis and biological evaluation of novel pyridine derivatives as gut-selective NaPi2b inhibitors

Bioorganic & Medicinal Chemistry Letters, 2022
We previously reported thiophene derivatives as gut-selective (minimally systemic) and potent sodium-dependent phosphate transport protein 2b (SLC34A2, NaPi2b) inhibitors. However, these derivatives did not suppress phosphate absorption form the intestinal tract in Sprague-Dawley (SD) rats.
Yasunobu Ushiki, Kenichi Kawabe, Kumiko Yamamoto-Okada, Fumito Uneuchi, Yuta Asanuma, Chitose Yamaguchi, Hiroshi Ohta, Tsuyoshi Shibata, Tomohiro Abe, Lisa Okumura-Kitajima, Yuki Kosai, Mayumi Endo, Katsumasa Otake, Eiji Munetomo, Teisuke Takahashi, Hiroyuki Kakinuma   +15 more
openaire   +3 more sources

Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b [PDF]

BMC Cancer, 2017
Background To characterize the expression of the membrane transporter NaPi2b and antigen targeted by the MX35 antibody in ovarian tumor samples. The current interest to develop monoclonal antibody based therapy of ovarian cancer by targeting NaPi2b ...
Kristina Levan, Matin Mehryar, Constantina Mateoiu, Per Albertsson, Tom Bäck, Karin Sundfeldt   +5 more
doaj   +3 more sources